Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study

被引:9
|
作者
Prosberg, Michelle V. [1 ]
Vester-Andersen, Marianne K. [1 ]
Andersson, Mikael [2 ]
Jess, Tine [2 ]
Andersen, Jon T. [3 ]
Vind, Ida [1 ]
Bendtsen, Flemming [1 ]
机构
[1] Univ Copenhagen, Hvidovre Hosp, Gastrounit, Med Sect, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark
[2] Natl Hlth Surveillance & Res, Dept Epidemiol Res, Copenhagen, Denmark
[3] Rigshosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark
关键词
ulcerative colitis; compliance; recurrence; INFLAMMATORY-BOWEL-DISEASE; MEDICATION NONADHERENCE; SURGERY RATES; MESALAZINE; MESALAMINE; ADHERENCE; DIAGNOSIS; PERSISTENCE; PREDICTORS; PHENOTYPE;
D O I
10.1097/MIB.0000000000000700
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Noncompliance to long-term medical therapy is a well-known problem among patients treated for ulcerative colitis, but studies of long-term consequences in unselected patients are lacking. The authors aimed to determine the risk of recurrence according to long-term compliance with oral 5-aminosalicylic acid among unselected patients with ulcerative colitis. Methods: The authors conducted a 7-year follow-up study of a population-based inception cohort of 243 Danish patients with ulcerative colitis diagnosed from 2003 to 2004. Compliance was defined as consumption of >= 80% of prescribed oral 5-aminosalicylic acid. Data were collected from medical records and the Danish National Prescription Database. They performed Cox regression analysis with adjustments for demographic and clinical characteristics to examine risk of recurrence (defined by increased use of oral 5-Aminosalicylic Acid, other additional treatment, or colectomy) in compliant versus noncompliant patients. Results: In total, 182 patients (75%) experienced at least 1 recurrence during follow-up. For the first year after diagnosis, risk of recurrence did not differ significantly between compliant and noncompliant patients. For 1 to 3 years (hazard ratio: 0.46, 95% CI, 0.33-0.63) and 3 to 8 years (hazard ratio: 0.42, 95% CI, 0.32-0.55) after diagnosis, risk of recurrence was significantly decreased among noncompliant patients compared with that of compliant patients. Conclusions: This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis. This is unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Results may instead reflect that patients during recurrence-free periods through self-management choose not to take their medication.
引用
收藏
页码:925 / 932
页数:8
相关论文
共 50 条
  • [41] Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study
    Cottet, Vanessa
    Jooste, Valerie
    Fournel, Isabelle
    Bouvier, Anne-Marie
    Faivre, Jean
    Bonithon-Kopp, Claire
    GUT, 2012, 61 (08) : 1180 - 1186
  • [42] Long-Term Direct Costs Before and After Proctocolectomy for Ulcerative Colitis: A Population-Based Study in Olmsted County, Minnesota
    Holubar, Stefan D.
    Long, Kirsten Hall
    Loftus, Edward V., Jr.
    Wolff, Bruce G.
    Pemberton, John H.
    Cima, Robert R.
    DISEASES OF THE COLON & RECTUM, 2009, 52 (11) : 1815 - 1823
  • [43] Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study
    Shehab, Mohammad
    Alrashed, Fatema
    Alyaseen, Munerah
    Safar, Zainab
    Adekunle, Tunrayo
    Alfadhli, Ahmad
    Bessissow, Talat
    VACCINES, 2024, 12 (04)
  • [44] COATED ORAL 5-AMINOSALICYLIC ACID (CLAVERSAL) IS EQUIVALENT TO SULFASALAZINE FOR REMISSION MAINTENANCE IN ULCERATIVE-COLITIS - A DOUBLE-BLIND-STUDY
    ARDIZZONE, S
    PETRILLO, M
    MOLTENI, P
    DESIDERI, S
    PORRO, GB
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 21 (04) : 287 - 289
  • [45] Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial
    Shen, Zhaofeng
    Zheng, Kai
    Zou, Jiandong
    Gu, Peiqing
    Xing, Jing
    Zhang, Lu
    Zhu, Lei
    Shen, Hong
    TRIALS, 2021, 22 (01)
  • [46] The long-term incidence of dysplasia and colorectal cancer in a Crohn's colitis population-based cohort
    Gatenby, Grace
    Glyn, Tamara
    Pearson, John
    Gearry, Richard
    Eglinton, Tim
    COLORECTAL DISEASE, 2021, 23 (09) : 2399 - 2406
  • [47] Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
    Peters, Charlotte P.
    Eshuis, Emma J.
    Toxopeus, Florien M.
    Hellemons, Merel E.
    Jansen, Jeroen M.
    D'Haens, Geert R. A. M.
    Fockens, Paul
    Stokkers, Pieter C. F.
    Tuynman, Hans A. R. E.
    van Bodegraven, Adriaan A.
    Ponsioen, Cyriel Y.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (08): : 866 - 875
  • [48] Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population-based study
    Song, Eun Mi
    Lee, Ho-Su
    Kim, Ye-Jee
    Oh, Eun Hye
    Ham, Nam Seok
    Kim, Jeongseok
    Hwang, Sung Wook
    Park, Sang Hyoung
    Yang, Dong-Hoon
    Ye, Byong Duk
    Byeon, Jeong-Sik
    Myung, Seung-Jae
    Yang, Suk-Kyun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (06) : 1011 - 1017
  • [49] Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies
    Tsai, Lester
    Nguyen, Nghia H.
    Ma, Christopher
    Prokop, Larry J.
    Sandborn, William J.
    Singh, Siddharth
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 2451 - 2461
  • [50] Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease
    Sandborn, WJ
    Loftus, EV
    Colombel, JF
    Fleming, KA
    Seibold, F
    Homburger, HA
    Sendid, T
    Chapman, RW
    Tremaine, WJ
    Kaul, DK
    Wallace, J
    Harmsen, WS
    Zinsmeister, AR
    Targan, SR
    INFLAMMATORY BOWEL DISEASES, 2001, 7 (03) : 192 - 201